Anwaar Mohammed Saeed MD

Oncology•Westwood, KS

Gastrointestinal Cancer

Associate Professor

Join to View Full Profile

2650 Shawnee Mission PkwyWestwood, KS 66205
Phone+1 913-588-6029
Fax+1 913-588-4085

Education & Training

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Missouri-Kansas City School of MedicineResidency, Internal Medicine, 2008 - 2011
Arabian Gulf University College of MedicineClass of 2005

Certifications & Licensure

PA State Medical License 2023 - 2026
KS State Medical License 2016 - 2023
WI State Medical License 2014 - 2017
MO State Medical License 2008 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Start of enrollment: 2017 Oct 16
ACTIVE_NOT_RECRUITING
PHASE3
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study Start of enrollment: 2018 Jan 19
SUSPENDED
PHASE3
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Start of enrollment: 2018 Jun 25
ACTIVE_NOT_RECRUITING
PHASE2
Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies Start of enrollment: 2018 Oct 22
RECRUITING
PHASE1, PHASE2
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer Start of enrollment: 2018 Sep 14
Completed
Phase 2
Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) Start of enrollment: 2019 Feb 06
Active, not recruiting
Phase 2
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma Start of enrollment: 2020 Jan 09
Active, not recruiting
Phase 1, Phase 2
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer Start of enrollment: 2019 Dec 02
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
9-ING-41 in Patients with Advanced Cancers Start of enrollment: 2019 Jan 04
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).
Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, Dan G Duda, Robin Park
Future Oncology. 2025-03-28
Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials.
Mohamed Saad Sayed, Yassine Alami Idrissi, Owais Ahmed, Sama Hesham Samir, Swastik Pandita
Medical Oncology. 2025-03-21
Age-Related Differences in Gastric Adenocarcinoma from 2000-2020: A SEER Database Analysis.
Abdul Qahar Khan Yasinzai, Anwaar Saeed
Journal of Gastrointestinal Cancer. 2025-03-13

Press Mentions

Cabozantinib plus Durvalumab Shows Efficacy in Subset of Patients with Colorectal CancerJanuary 28th, 2022
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022January 18th, 2022
UW Clinical Trial Holds Hope for Lung Cancer PatientsSeptember 20th, 2016